SURVYR

MYGN

Myriad Genetics, Inc.
$6.63
+$0.34 (5.41%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-66%-46%-26%-5%+15%Oct 2025Oct 2026Apr 202652w high $8.5052w low $2.74
MYGNSPY
Wall St. Highest PT $8.00 (+20.7%) Wall St. Avg PT $4.49 (-32.3%)
$3$4$6$7$8POC $5Hi $8Avg $4
Underwater Drawdown %Max DD -65.0%Current -18.9%
0.0%-65.0%
Relative Strength vs SPY-32.1% vs SPYUnderperforming
+89%0%-89%
1W
+$1.06 (19.03%)
1M
+$2.39 (56.37%)
3M
+$1.59 (31.55%)
6M
+$1.95 (41.67%)
YTD
+$0.48 (7.80%)
1Y
−$1.50 (18.45%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Hold
8 analysts · mean score 3.11
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$6.63
Average target$4.49
−$2.14 (−32.3%) downsideaverage target vs current price
CurrentAverageMedian
Low$2.50
Median$4.49
High$8.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-13 · TD Cowen reiterated Hold on MYGN
Reiterated
2026-10-02 · Craig-Hallum reiterated Buy on MYGN
Reiterated
2026-09-09 · UBS reiterated Neutral on MYGN
Downgrade
2026-09-01 · Piper Sandler downgraded MYGN from Overweight to Underweight
Reiterated
2026-08-18 · Stephens & Co. reiterated Equal-Weight on MYGN
Reiterated
2026-08-03 · Wells Fargo reiterated Equal-Weight on MYGN
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$529.9M
P/E (next 12 months, estimated)-9.4
52-week range$2.74 – $8.50
Revenue growth (latest quarter vs a year ago)-10.5%
Dividend yieldNo dividend
Analyst consensusHold (8)
Average analyst price target$4.49 (-32%)

What they do

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for MYGN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MYGN earningsNext report in 6 days
Next report · quarter Sep 2026
Wed Nov 4, 2026After the close
EPS consensus-$0.20 range -$0.27–-$0.15
Revenue consensus$191.3M 8 analysts
Last 4 quarters · EPS vs estimate
Jul 30, 2026-$0.25est -$0.06−332.7%Below estimates
May 5, 2026-$0.09est -$0.07−34.7%Below estimates
Feb 23, 2026$0.04est -$0.02+348.3%Above estimates
Aug 5, 2025$0.05est -$0.01+724.2%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 01:31:33 ET
24-0824-1125-0225-0525-0826-0226-0526-07-0.250.06
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$190.7M-10.5%
2026-03-31$200.4M–
2025-12-31$209.8M–
2025-09-30$205.7M–
2025-06-30$213.1M–

Recent dividends

2009-07-01: $1.750 · 2009-06-15: $1.750

News & catalysts

More news
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln
Nasdaq · Oct 20
Rating changes
Reiterated
2026-10-13 · TD Cowen reiterated Hold on MYGN
Reiterated
2026-10-02 · Craig-Hallum reiterated Buy on MYGN
Reiterated
2026-09-09 · UBS reiterated Neutral on MYGN
Downgrade
2026-09-01 · Piper Sandler downgraded MYGN from Overweight to Underweight
Reiterated
2026-08-18 · Stephens & Co. reiterated Equal-Weight on MYGN
Reiterated
2026-08-03 · Wells Fargo reiterated Equal-Weight on MYGN

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-21 01:31:33 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026